Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | PLG | P00747 | 2/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.38 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30872131 | 0.85 | ALDH1A1 (0.41) | CNR2ALDH1A1GAAL3MBTL1ABCB11 | |
| SCHEMBL30872128 | 0.85 | ALDH1A1 (0.41) | CNR2ALDH1A1GAAL3MBTL1ABCB11 | |
| SCHEMBL24355439 | 0.84 | GAA (0.49) | CNR2ALDH1A1GAAL3MBTL1ABCB11 | |
| SCHEMBL29272435 | 0.83 | CNR2 (0.44) | CNR2ALDH1A1SMARCA2SMARCA4 | |
| SCHEMBL2183357 | 0.82 | GAA (0.40) | CNR2ALDH1A1GAAL3MBTL1ABCB11 | |
| SCHEMBL13331893 | 0.78 | AKR1C3 (0.44) | SMARCA2SMARCA4 | |
| SCHEMBL1970633 | 0.78 | CYP19A1 (0.53) | CNR2ABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL13563525 | 0.78 | GAA (0.49) | CNR2ALDH1A1GAAL3MBTL1CYP1A2 | |
| SCHEMBL29922800 | 0.78 | DGAT1 (0.49) | CNR2ALDH1A1GAAL3MBTL1MAOB | |
| SCHEMBL17796511 | 0.78 | DGAT1 (0.49) | CNR2ALDH1A1GAAL3MBTL1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509595-B1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD (GB) | 2018-04-11 | — | — | EP | disclosed |
| EP-2509595-B1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD (GB) | 2018-04-11 | — | — | EP | disclosed |
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| EP-2370428-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-08-10 | — | — | EP | disclosed |
| EP-2370428-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-08-10 | — | — | EP | disclosed |
| US-20160045512-A1 | Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection | RESPIVERT LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| US-20160045512-A1 | Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection | RESPIVERT LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| CN-102762204-B | Inhibitors of hematopoietic cell kinase (P59-HCK) and their use in the treatment of influenza infections | RESPIVERT LTD | 2014-11-19 | — | — | CN | disclosed |
| CN-102341384-B | P38 map kinase inhibitors | RESPIVERT LTD | 2014-11-12 | — | — | CN | disclosed |
| CN-102762204-A | Inhibitors of hematopoietic cell kinase (P59-HCK) and their use in the treatment of influenza infections | RESPIVERT LTD | 2012-10-31 | — | — | CN | disclosed |
| EP-2509595-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | Respivert Limited (GB) | 2012-10-17 | — | — | EP | disclosed |
| US-20120244120-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD. (GB) | 2012-09-27 | — | — | US | disclosed |
| CN-102341384-A | P38 map kinase inhibitors | RESPIVERT LTD | 2012-02-01 | — | — | CN | disclosed |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-12-01 | — | — | US | disclosed |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-12-01 | — | — | US | disclosed |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-12-01 | — | — | US | disclosed |
| EP-2370428-A1 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011070368-A1 | ANTIVIRAL USE OF UREA COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070369-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010067131-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | HCK, CDK9, PHKG1 | CNR2 3943/4885ALDH1A1 3995/4885GAA 3297/4885 |
| US-20120244120-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | HCK, CDK9, TTK | CNR2 4085/4885ALDH1A1 3370/4885GAA 3316/4885 |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | CNR2 3734/4885ALDH1A1 2317/4885GAA 2821/4885 |
| US-20160045512-A1 | Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection | HCK, CDK9, TTK | CNR2 4085/4885ALDH1A1 3370/4885GAA 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.